Actelion board battlelines drawn as Elliott slate hits back
This article was originally published in Scrip
Members of the slate being nominated to the Actelion board by Elliott Advisors have written to the Swiss company's shareholders refuting allegations about their strategic intent and restating their own criticisms of the current board's track record. In a letter to Actelion shareholders, the six nominees assert that they are independent of the hedge fund, which is Actelion's largest shareholder, and are intent on working with all shareholders to achieve a sustainable business plan that best meets the needs of stakeholders.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.